{"id":1629,"date":"2023-03-29T13:48:08","date_gmt":"2023-03-29T13:48:08","guid":{"rendered":"http:\/\/wecare.sitedev.pt\/referencias-bibliograficas\/pourquoi-references-3\/"},"modified":"2023-03-29T13:49:54","modified_gmt":"2023-03-29T13:49:54","slug":"warum-3","status":"publish","type":"referencias-biblio","link":"https:\/\/wecare-medicalcannabis.com\/de\/quellenangaben\/warum-3\/","title":{"rendered":"WARUM – QUELLENANGABEN"},"content":{"rendered":"
\n
\n
\n
\n
(ALLGEMEIN)<\/h5>\n

1. Schmidt-Wolf G, Cremer-Schaeffer P. 3 Jahre Cannabis als Medizin \u2013 Zwischenergebnisse der Cannabisbegleiterhebung. Bundesgesundheitsblatt. 2021;64: 368-377.<\/p>\n

2. US National Library of Medicine. ClinicalTrials.gov: Cannabis studies. Accessible ici: https:\/\/clinicaltrials.gov\/ct2\/results?cond=&term=Cannabis&cntry=&state=&city=&dist= (consult\u00e9 le 1 September 2021).<\/p>\n<\/div>\n

\n
(SCHMERZ)<\/h5>\n

3. Di Marzo V, Piscitelli F. The endocannabinoid system and its modulation by phytocannabinoids. Neurotherapeutics. 2015;12(4): 692-8.<\/p>\n

4. Woodhams SG, Chapman V, Finn DP, Hohmann AG, Neugebauer V. The cannabinoid system and pain. Neuropharmacology. 2017;124: 105-20.<\/p>\n

5. Health Canada. Information for Health Care Professionals: Cannabis and the cannabinoids. October 2018. ISBN: 978-0-660-27828-5.<\/p>\n

6. Horlemann J, Sch\u00fcrmann N. DGS-PraxisLeitlinie: Cannabis in der Schmerzmedizin. Version 1.0. 2018. ISBN: 978-3-9817530-4-2.<\/p>\n

7. H\u00e4user W, Finn DP, Kalso E, et al. European Pain Federation (EFIC) position paper on appropriate use of cannabis-based medicines and medical cannabis for chronic pain management. Eur J Pain. 2018;22(9): 1547-1564.<\/p>\n<\/div>\n

\n
(SPASTIK)<\/h5>\n

8. Sezer N, Akkus S, Ugurlu FG. Chronic complications of spinal cord injury. World J Orthop. 2015;6(1): 24-33.<\/p>\n

9. Centonze D. Advances in the management of multiple sclerosis spasticity: multiple sclerosis spasticity nervous pathways. Eur Neurol. 2014;72(suppl 1): 6-8.<\/p>\n

10. Flachenecker P. A new multiple sclerosis spasticity treatment option: effect in everyday clinical practice and cost-effectiveness in Germany. Expert Rev Neurother. 2013;13(3 suppl 1): 15-19.<\/p>\n

11. Sativex\u00ae Summary of Product Characteristics. GW Pharma Ltd. August 2020.<\/p>\n

12. Platz T. et al., Therapie des spastischen Syndroms, S2k-Leitlinie, 2018, in: Deutsche Gesellschaft f\u00fcr Neurologie (Hrsg.), Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie. Accessed November 9, 2021. Online: www.dgn.org\/leitlinien.<\/p>\n

13. Solari A, Giordano A, Sastre-Garriga J, et al. for the EAN guideline task force. EAN guideline on palliative care of people with severe, progressive multiple sclerosis. Eur J Neurol. 2020;27(8): 1510-29.<\/p>\n<\/div>\n

\n
(APPETITLOSIGKEIT)<\/h5>\n

14. Ezeoke CC, Morley JE. Pathophysiology of anorexia in the cancer cachexia syndrome. J Cachexia Sarcopenia Muscle. 2015;6(4): 287-302.<\/p>\n

15. Radbruch L, Elsner F, Trottenberg P, Strasser F, Fearon K. Clinical Practice Guidelines on Cancer Cachexia in Advanced Cancer Patients. Aachen, Department of Palliative Medicine: European Palliative Care Research Collaborative; 2010.<\/p>\n

16. Arends J, Bachmann P, Baracos V, et al. ESPEN guidelines on nutrition in cancer patients. Clin Nutr. 2017;36(1): 11-48.<\/p>\n<\/div>\n<\/div>\n

\n
\n
(\u00dcBELKEIT & ERBRECHEN)<\/h5>\n

17. Martin BR, Wiley JL. Mechanism of action of cannabinoids: how it may lead to treatment of cachexia, emesis, and pain. J Support Oncol. 2004;2(4): 305-14; discussion 314-6.<\/p>\n

18. Tram\u00e8r MR, Carroll D, Campbell FA, Reynolds DJ, Moore RA, McQuay HJ. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ. 2001;323(7303): 16-21.<\/p>\n

19. Preuss K-J, von Rothkirch C. The Market for Medical Cannabis in Germany. 1st ed. Hamburg: EPC Healthcare GmbH. 2020.<\/p>\n

20. Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA. 2015;313(24): 2456-2473. Erratum in: JAMA. 2015;314(5): 520. Erratum in: JAMA. 2015;314(8): 837. Erratum in: JAMA. 2015;314(21): 2308. Erratum in: JAMA. 2016;315(14): 1522.<\/p>\n

21. Grimison P, Mersiades A, Kirby A, et al. Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial. Ann Oncol. 2020. 31(11): 1553-60.<\/p>\n

22. German Guideline Program in Oncology (GGPO). Extended S3 Guideline: Palliative care for patients with incurable cancer. V2.2. September 2020. Accessed November 9, 2021: https:\/\/www.leitlinienprogramm-onkologie.de\/german-guideline-program-in-oncology\/<\/p>\n

23. Berger MJ, Ettinger DS, Aston J, et al. NCCN Guidelines Insights: Antiemesis, Version 2.2017. J Natl Compr Canc Netw. 2017;15(7): 883-93.<\/p>\n<\/div>\n

\n
(SCHLAFST\u00d6RUNGEN)<\/h5>\n

24. Kesner AJ, Lovinger DM. Cannabinoids, endocannabinoids and sleep. Front Mol Neurosci. 2020;13: 125.<\/p>\n

25. Russo EB, Guy GW, Robson PJ. Cannabis, pain, and sleep: lessons from therapeutic clinical trials of Sativex, a cannabis-based medicine. Chem Biodivers. 2007;4(8): 1729-43.<\/p>\n<\/div>\n

\n
(EPILEPSIE)<\/h5>\n

26. Perucca E. Cannabinoids in the treatment of epilepsy: hard evidence at last? J Epilepsy Res. 2017;7(2): 61-76.<\/p>\n

27. Rosenberg EC, Tsien RW, Whalley BJ, Devinsky O. Cannabinoids and epilepsy. Neurotherapeutics. 2015;12(4): 747-68.<\/p>\n

28. Epidyolex\u00ae Summary of Product Characteristics. GW Pharma. July 2021.<\/p>\n

29. McCoy B, Wang L, Zak M, et al. A prospective open-label trial of a CBD\/THC cannabis oil in dravet syndrome. Ann Clin Transl Neurol. 2018;5(9): 1077-88.<\/p>\n

30. Huntsman RJ, Tang-Wai R, Alcorn J, et al. Dosage related efficacy and tolerability of cannabidiol in children with treatment-resistant epileptic encephalopathy: preliminary results of the CARE-E study. Front Neurol. 2019;10: 716.<\/p>\n

31. Tzadok M, Uliel-Siboni S, Linder I, et al. CBD-enriched medical cannabis for intractable pediatric epilepsy: The current Israeli experience. Seizure. 2016;35: 41-4.<\/p>\n

32. Caraballo R, Valenzuela GR. Cannabidiol-enriched medical cannabis as add-on therapy in children with treatment-resistant West syndrome: a study of eight patients. Seizure. 2021; 92: 238-43.<\/p>\n<\/div>\n

\n
(ANGSTST\u00d6RUNGEN)<\/h5>\n

33. Maldonado R, Caba\u00f1ero D, Mart\u00edn-Garc\u00eda E. The endocannabinoid system in modulating fear, anxiety, and stress. Dialogues Clin Neurosci. 2020;22(3): 229-39.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

(ALLGEMEIN) 1. Schmidt-Wolf G, Cremer-Schaeffer P. 3 Jahre Cannabis als Medizin \u2013 Zwischenergebnisse der Cannabisbegleiterhebung. Bundesgesundheitsblatt. 2021;64: 368-377. 2. US National Library of Medicine. ClinicalTrials.gov: Cannabis studies. Accessible ici: https:\/\/clinicaltrials.gov\/ct2\/results?cond=&term=Cannabis&cntry=&state=&city=&dist= (consult\u00e9 le 1 September 2021). (SCHMERZ) 3. Di Marzo V, Piscitelli F. The endocannabinoid system and its modulation by phytocannabinoids. Neurotherapeutics. 2015;12(4): 692-8. 4. Woodhams<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"inline_featured_image":false,"footnotes":""},"biblio-cats":[69],"class_list":["post-1629","referencias-biblio","type-referencias-biblio","status-publish","hentry","biblio-cats-profissionais-categorias"],"acf":[],"yoast_head":"\nWARUM - QUELLENANGABEN - WeCare<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/wecare-medicalcannabis.com\/de\/quellenangaben\/warum-3\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"WARUM - QUELLENANGABEN - WeCare\" \/>\n<meta property=\"og:description\" content=\"(ALLGEMEIN) 1. Schmidt-Wolf G, Cremer-Schaeffer P. 3 Jahre Cannabis als Medizin \u2013 Zwischenergebnisse der Cannabisbegleiterhebung. Bundesgesundheitsblatt. 2021;64: 368-377. 2. US National Library of Medicine. ClinicalTrials.gov: Cannabis studies. Accessible ici: https:\/\/clinicaltrials.gov\/ct2\/results?cond=&term=Cannabis&cntry=&state=&city=&dist= (consult\u00e9 le 1 September 2021). (SCHMERZ) 3. Di Marzo V, Piscitelli F. The endocannabinoid system and its modulation by phytocannabinoids. Neurotherapeutics. 2015;12(4): 692-8. 4. Woodhams\" \/>\n<meta property=\"og:url\" content=\"https:\/\/wecare-medicalcannabis.com\/de\/quellenangaben\/warum-3\/\" \/>\n<meta property=\"og:site_name\" content=\"WeCare\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-29T13:49:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/wecare-medicalcannabis.com\/wp-content\/uploads\/2022\/12\/2-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1632\" \/>\n\t<meta property=\"og:image:height\" content=\"918\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data1\" content=\"4\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/wecare-medicalcannabis.com\/de\/quellenangaben\/warum-3\/\",\"url\":\"https:\/\/wecare-medicalcannabis.com\/de\/quellenangaben\/warum-3\/\",\"name\":\"WARUM - QUELLENANGABEN - WeCare\",\"isPartOf\":{\"@id\":\"https:\/\/wecare-medicalcannabis.com\/de\/#website\"},\"datePublished\":\"2023-03-29T13:48:08+00:00\",\"dateModified\":\"2023-03-29T13:49:54+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/wecare-medicalcannabis.com\/de\/quellenangaben\/warum-3\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/wecare-medicalcannabis.com\/de\/quellenangaben\/warum-3\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/wecare-medicalcannabis.com\/de\/quellenangaben\/warum-3\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"In\u00edcio\",\"item\":\"https:\/\/wecare-medicalcannabis.com\/de\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"WARUM – QUELLENANGABEN\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/wecare-medicalcannabis.com\/de\/#website\",\"url\":\"https:\/\/wecare-medicalcannabis.com\/de\/\",\"name\":\"WeCare\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/wecare-medicalcannabis.com\/de\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/wecare-medicalcannabis.com\/de\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"de\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/wecare-medicalcannabis.com\/de\/#organization\",\"name\":\"WeCare\",\"url\":\"https:\/\/wecare-medicalcannabis.com\/de\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\/\/wecare-medicalcannabis.com\/de\/#\/schema\/logo\/image\/\",\"url\":\"http:\/\/wecare.sitedev.pt\/wp-content\/uploads\/2022\/12\/logo-wecare.png\",\"contentUrl\":\"http:\/\/wecare.sitedev.pt\/wp-content\/uploads\/2022\/12\/logo-wecare.png\",\"width\":121,\"height\":72,\"caption\":\"WeCare\"},\"image\":{\"@id\":\"https:\/\/wecare-medicalcannabis.com\/de\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"WARUM - QUELLENANGABEN - WeCare","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/wecare-medicalcannabis.com\/de\/quellenangaben\/warum-3\/","og_locale":"de_DE","og_type":"article","og_title":"WARUM - QUELLENANGABEN - WeCare","og_description":"(ALLGEMEIN) 1. Schmidt-Wolf G, Cremer-Schaeffer P. 3 Jahre Cannabis als Medizin \u2013 Zwischenergebnisse der Cannabisbegleiterhebung. Bundesgesundheitsblatt. 2021;64: 368-377. 2. US National Library of Medicine. ClinicalTrials.gov: Cannabis studies. Accessible ici: https:\/\/clinicaltrials.gov\/ct2\/results?cond=&term=Cannabis&cntry=&state=&city=&dist= (consult\u00e9 le 1 September 2021). (SCHMERZ) 3. Di Marzo V, Piscitelli F. The endocannabinoid system and its modulation by phytocannabinoids. Neurotherapeutics. 2015;12(4): 692-8. 4. Woodhams","og_url":"https:\/\/wecare-medicalcannabis.com\/de\/quellenangaben\/warum-3\/","og_site_name":"WeCare","article_modified_time":"2023-03-29T13:49:54+00:00","og_image":[{"width":1632,"height":918,"url":"https:\/\/wecare-medicalcannabis.com\/wp-content\/uploads\/2022\/12\/2-1.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Gesch\u00e4tzte Lesezeit":"4\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/wecare-medicalcannabis.com\/de\/quellenangaben\/warum-3\/","url":"https:\/\/wecare-medicalcannabis.com\/de\/quellenangaben\/warum-3\/","name":"WARUM - QUELLENANGABEN - WeCare","isPartOf":{"@id":"https:\/\/wecare-medicalcannabis.com\/de\/#website"},"datePublished":"2023-03-29T13:48:08+00:00","dateModified":"2023-03-29T13:49:54+00:00","breadcrumb":{"@id":"https:\/\/wecare-medicalcannabis.com\/de\/quellenangaben\/warum-3\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/wecare-medicalcannabis.com\/de\/quellenangaben\/warum-3\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/wecare-medicalcannabis.com\/de\/quellenangaben\/warum-3\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"In\u00edcio","item":"https:\/\/wecare-medicalcannabis.com\/de\/"},{"@type":"ListItem","position":2,"name":"WARUM – QUELLENANGABEN"}]},{"@type":"WebSite","@id":"https:\/\/wecare-medicalcannabis.com\/de\/#website","url":"https:\/\/wecare-medicalcannabis.com\/de\/","name":"WeCare","description":"","publisher":{"@id":"https:\/\/wecare-medicalcannabis.com\/de\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/wecare-medicalcannabis.com\/de\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"de"},{"@type":"Organization","@id":"https:\/\/wecare-medicalcannabis.com\/de\/#organization","name":"WeCare","url":"https:\/\/wecare-medicalcannabis.com\/de\/","logo":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/wecare-medicalcannabis.com\/de\/#\/schema\/logo\/image\/","url":"http:\/\/wecare.sitedev.pt\/wp-content\/uploads\/2022\/12\/logo-wecare.png","contentUrl":"http:\/\/wecare.sitedev.pt\/wp-content\/uploads\/2022\/12\/logo-wecare.png","width":121,"height":72,"caption":"WeCare"},"image":{"@id":"https:\/\/wecare-medicalcannabis.com\/de\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/wecare-medicalcannabis.com\/de\/wp-json\/wp\/v2\/referencias-biblio\/1629","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/wecare-medicalcannabis.com\/de\/wp-json\/wp\/v2\/referencias-biblio"}],"about":[{"href":"https:\/\/wecare-medicalcannabis.com\/de\/wp-json\/wp\/v2\/types\/referencias-biblio"}],"author":[{"embeddable":true,"href":"https:\/\/wecare-medicalcannabis.com\/de\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/wecare-medicalcannabis.com\/de\/wp-json\/wp\/v2\/comments?post=1629"}],"version-history":[{"count":2,"href":"https:\/\/wecare-medicalcannabis.com\/de\/wp-json\/wp\/v2\/referencias-biblio\/1629\/revisions"}],"predecessor-version":[{"id":1635,"href":"https:\/\/wecare-medicalcannabis.com\/de\/wp-json\/wp\/v2\/referencias-biblio\/1629\/revisions\/1635"}],"wp:attachment":[{"href":"https:\/\/wecare-medicalcannabis.com\/de\/wp-json\/wp\/v2\/media?parent=1629"}],"wp:term":[{"taxonomy":"biblio-cats","embeddable":true,"href":"https:\/\/wecare-medicalcannabis.com\/de\/wp-json\/wp\/v2\/biblio-cats?post=1629"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}